Semaglutide: Research & Studies

Research Overview#

Semaglutide has one of the most extensive and robust clinical evidence bases among GLP-1 receptor agonists, spanning four major phase 3 clinical trial programs: SUSTAIN (type 2 diabetes, injectable), PIONEER (type 2 diabetes, oral), STEP (obesity/weight management), and SELECT (cardiovascular outcomes). These programs collectively enrolled over 25,000 participants across more than 20 randomized controlled trials, establishing high-quality evidence for multiple indications.

The evidence level for semaglutide is classified as high based on multiple large randomized controlled trials, active-comparator data, positive cardiovascular outcomes trials, FDA approval for three indications, and the most extensive post-marketing experience of any modern GLP-1 agonist (since 2017).

SUSTAIN Clinical Trial Program (Type 2 Diabetes, Injectable)#

The SUSTAIN program established the efficacy and safety of injectable semaglutide for type 2 diabetes mellitus across diverse clinical scenarios.

SUSTAIN-1: Monotherapy#

SUSTAIN-1 evaluated semaglutide (0.5 mg and 1.0 mg weekly) as monotherapy in 388 adults with T2D inadequately controlled by diet and exercise over 30 weeks. Both doses demonstrated significant HbA1c reductions: -1.45% (0.5 mg) and -1.55% (1.0 mg) versus +0.02% (placebo).

SUSTAIN-2: versus Sitagliptin#

In 1,231 patients on metformin with or without other oral agents, semaglutide 1.0 mg reduced HbA1c by -1.6% versus -0.5% with sitagliptin 100 mg daily, demonstrating clear superiority over DPP-4 inhibitor therapy.

SUSTAIN-6: Cardiovascular Outcomes#

SUSTAIN-6 (Marso et al., 2016; PMID 27633186) was a pre-approval cardiovascular safety trial that enrolled 3,297 patients with T2D and established cardiovascular disease or high cardiovascular risk, with a median follow-up of 2.1 years.

The primary endpoint (first occurrence of cardiovascular death, non-fatal MI, or non-fatal stroke) was significantly reduced with semaglutide: HR 0.74 (95% CI 0.58-0.95, P=0.02), representing a 26% relative risk reduction. The benefit was driven primarily by reductions in non-fatal stroke (HR 0.61) and non-fatal MI (HR 0.74). Cardiovascular death was numerically lower but not individually significant.

A notable finding was a significant increase in diabetic retinopathy complications (HR 1.76), attributed to the rapid HbA1c improvement rather than a direct drug effect. This signal led to enhanced monitoring recommendations for patients with pre-existing retinopathy.

SUSTAIN-7: versus Dulaglutide#

Semaglutide demonstrated superiority over dulaglutide (another once-weekly GLP-1 agonist) at both dose comparisons: semaglutide 0.5 mg versus dulaglutide 0.75 mg, and semaglutide 1.0 mg versus dulaglutide 1.5 mg, for both HbA1c reduction and weight loss.

SUSTAIN FORTE: 2 mg Dose#

SUSTAIN FORTE evaluated semaglutide 2 mg versus 1 mg in 961 patients with T2D on metformin, demonstrating additional HbA1c reduction of -0.2% with the higher dose, supporting the 2022 approval of the 2 mg Ozempic dose.

PIONEER Clinical Trial Program (Type 2 Diabetes, Oral)#

The PIONEER program evaluated oral semaglutide (Rybelsus) across 10 trials, establishing it as the first oral GLP-1 receptor agonist.

PIONEER 1: Oral Monotherapy#

Oral semaglutide 14 mg daily reduced HbA1c by -1.5% versus -0.0% placebo at 26 weeks in treatment-naive T2D patients. Weight loss was -3.7 kg versus -1.4 kg.

PIONEER 2: versus Empagliflozin#

PIONEER 2 (Rodbard et al., 2019; PMID 31169736) compared oral semaglutide 14 mg to empagliflozin 25 mg (an SGLT2 inhibitor) in 822 patients. Oral semaglutide demonstrated superior HbA1c reduction (-1.3% vs -0.8% at 26 weeks) with comparable weight loss. This trial was notable for demonstrating that an oral peptide could outperform a standard-of-care oral diabetes agent.

PIONEER 4: versus Liraglutide#

Oral semaglutide 14 mg was non-inferior to injectable liraglutide 1.8 mg daily for HbA1c reduction and demonstrated superior weight loss, a remarkable result given the inherent bioavailability limitations of oral peptide delivery.

PIONEER 6: Cardiovascular Safety (Oral)#

PIONEER 6 confirmed cardiovascular safety of oral semaglutide in a high-risk T2D population (HR 0.79 for MACE, not statistically significant but numerically favorable).

STEP Clinical Trial Program (Obesity/Weight Management)#

The STEP program established semaglutide 2.4 mg as one of the most effective anti-obesity medications.

STEP 1: Obesity Without Diabetes#

STEP 1 (Wilding et al., 2021; PMID 33567185) was the pivotal 68-week trial in 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one comorbidity, excluding diabetes.

Results established semaglutide as a transformative anti-obesity therapy:

• Mean weight loss: 14.9% (semaglutide) versus 2.4% (placebo)
• 86.4% achieved ≥5% weight loss (vs 31.5% placebo)
• 69.1% achieved ≥10% weight loss (vs 12.0% placebo)
• 50.5% achieved ≥15% weight loss (vs 4.9% placebo)
• 32.0% achieved ≥20% weight loss (vs 1.7% placebo)
• Significant improvements in waist circumference, blood pressure, lipids, CRP, and quality of life

STEP 2: Obesity With Type 2 Diabetes#

In 1,210 adults with T2D and obesity, semaglutide 2.4 mg achieved 9.6% weight loss (vs 3.4% placebo) at 68 weeks. The lower weight loss magnitude compared to STEP 1 is consistent with the established observation that T2D attenuates pharmacological weight loss responses.

STEP 3: With Intensive Behavioral Therapy#

Semaglutide 2.4 mg combined with intensive behavioral therapy (including an initial low-calorie diet phase) achieved 16.0% weight loss at 68 weeks versus 5.7% with behavioral therapy alone, demonstrating additive benefit with lifestyle intervention.

STEP 4: Withdrawal Study#

STEP 4 randomized patients who had lost weight on semaglutide to either continue semaglutide or switch to placebo. The continuation group maintained weight loss (-17.4% from randomization), while the withdrawal group regained approximately two-thirds of the lost weight (+6.9% from randomization through week 68). This trial demonstrated that ongoing therapy is necessary to maintain weight loss.

STEP 5: Two-Year Efficacy#

STEP 5 provided the longest controlled data for semaglutide in obesity: 2.4 mg weekly maintained 15.2% weight loss at 104 weeks (2 years), demonstrating sustained efficacy with continued treatment.

SELECT Trial (Cardiovascular Outcomes in Obesity)#

Landmark Cardiovascular Benefit#

The SELECT trial (Lincoff et al., 2023; PMID 37952131) was a landmark double-blind, placebo-controlled trial evaluating semaglutide 2.4 mg weekly in 17,604 adults aged 45 years or older with established cardiovascular disease (prior MI, stroke, or symptomatic PAD) and BMI ≥27, without diabetes.

Over a mean follow-up of 39.8 months, semaglutide reduced the primary composite endpoint of cardiovascular death, non-fatal MI, or non-fatal stroke by 20%: HR 0.80 (95% CI 0.72-0.90, P<0.001). Individual components showed:

• Cardiovascular death: HR 0.85 (95% CI 0.71-1.01)
• Non-fatal MI: HR 0.72 (95% CI 0.61-0.85)
• Non-fatal stroke: HR 0.93 (95% CI 0.74-1.15)

Mean weight loss was 9.4% (semaglutide) versus 0.9% (placebo). The cardiovascular benefit appeared to exceed what would be predicted from weight loss alone, suggesting additional anti-inflammatory, anti-atherosclerotic, or plaque-stabilizing effects.

Significance#

SELECT established semaglutide as the first anti-obesity medication to demonstrate cardiovascular benefit in patients without diabetes, a milestone that expanded the therapeutic role of GLP-1 agonists beyond glucose control into cardiovascular risk reduction. This finding led to a supplemental FDA indication for cardiovascular risk reduction in adults with established CVD and overweight/obesity.

Expanded Indication Research#

Ongoing and recently completed research is evaluating semaglutide in additional settings:

• MASH/NASH: Semaglutide has shown improvement in hepatic steatosis and NASH resolution in the STEP-NASH trial, with phase 3 trials ongoing
• Heart failure with preserved ejection fraction (HFpEF): Studies demonstrate improvement in heart failure symptoms and exercise capacity with semaglutide-induced weight loss
• Chronic kidney disease: The FLOW trial demonstrated renal benefits of semaglutide in patients with T2D and CKD, including reduction in kidney disease progression
• Obstructive sleep apnea: Weight loss with semaglutide improved apnea-hypopnea index scores

Evidence Quality Assessment#

Key Research Gaps#

1. Long-term outcomes beyond 5 years: While SELECT provided ~3.3 years of follow-up, longer-term data on sustained cardiovascular benefit and weight maintenance are needed.

2. Body composition: The impact of semaglutide on lean body mass versus fat mass during sustained weight loss requires better characterization. Strategies for muscle preservation (resistance exercise, protein intake) during GLP-1 agonist therapy are under investigation.

3. Head-to-head with tirzepatide: Cross-trial comparisons suggest tirzepatide produces greater weight loss. Direct comparison data in obesity populations will inform clinical decision-making.

4. Weight regain after discontinuation: STEP 4 demonstrated substantial weight regain after stopping semaglutide. Optimal approaches to long-term management, including potential dose reduction strategies, need further study.

5. Oral formulation for obesity: Higher-dose oral semaglutide (25 mg and 50 mg) is under investigation for weight management, which could substantially expand access if efficacy approaches the injectable formulation.

6. Pediatric populations: Semaglutide trials in adolescents with obesity are ongoing, with initial data showing efficacy in adolescents aged 12-17.

Related Reading#

• Semaglutide overview and research guide
• Semaglutide dosing protocols
• Semaglutide molecular structure